https://doi.org/10.4081/ecj.2025.13110
Efficacy of intranasal naloxone compared to other administration routes in prehospital opioid overdose management and beyond: a narrative review
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 22 January 2025
Drug-related deaths in Italy, especially from opioid overdoses, increased by 6% among individuals aged 15-34 from 2014 to 2018. Opioid-related deaths rose by 6.6% in the 15-24 age group and by 5.4% in the 25-34 age group during this period. There is limited data on the effectiveness of different naloxone administration routes—intranasal (IN), intramuscular (IM), and intravenous (IV)—and no established guidelines for prehospital overdose management. Timely intervention is crucial to reduce overdose mortality. This review aims to assess the effectiveness of naloxone administration methods in opioid overdoses, focusing on prehospital settings and comparing IN, IM, and IV routes. A narrative review was conducted in accordance with PRISMA guidelines. The search included terms such as “naloxone,” “opioid overdose,” “intranasal administration,” and “prehospital emergency care,” with Boolean operators to refine the scope. The study selection was guided by the PICO framework (population, intervention, comparison, outcome). Studies were assessed for quality using the Dixon-Woods tool, and inclusion/exclusion criteria were applied. Studies will be selected based on populations treated with naloxone administered via intranasal, intramuscular, or intravenous routes, focusing on comparisons between these formulations in terms of onset time and intervention effectiveness. Out of 111 studies, five met the eligibility criteria. These studies showed that intranasal naloxone achieves higher plasma concentrations than intramuscular doses but with slower absorption and longer peak times. Additionally, intramuscular naloxone results in faster respiratory recovery and requires fewer doses. Intranasal naloxone has a bioavailability of 46.8% to 50.8% compared to intravenous naloxone, with efficacy outcomes varying by administration route. The review shows that intranasal naloxone, especially at a 2 mg dose, achieves plasma levels similar to intramuscular formulations and has linear pharmacokinetics across dosages. While its bioavailability is lower (46% to 50%) compared to intravenous administration, it is a safer and more practical option for non-clinical settings. Although intramuscular and intravenous routes work faster, the slower absorption of intranasal naloxone may help reduce withdrawal symptoms, supporting gradual dosing strategies. These findings emphasize the need for further research on optimizing naloxone dosing for synthetic opioid emergencies. This review highlights intravenous naloxone as the most effective route for opioid overdose treatment, with intramuscular and intranasal routes offering practical alternatives in prehospital settings. Intranasal naloxone, despite its lower bioavailability, provides a non-invasive option suitable for lay responders. Gradual dose escalation is recommended to minimize withdrawal symptoms. The increasing prevalence of synthetic opioids underscores the need for updated clinical guidelines on naloxone dosing and administration routes.
Downloads
UNODC. World Drug Report 2021. United Nations Office on Drugs and Crime. Available from: https://www.unodc.org/unodc/en/data-and-analysis/wdr2021.html
GBD 2019 Diseases and Injuries Collaborators. Global Burden of Disease Study 2019 (GBD 2019). Lancet 2020. Available from: https://www.thelancet.com/gbd
Presidenza del Consiglio dei Ministri, Dipartimento per le Politiche Antidroga. Relazione al Parlamento 2022. Available from: http://www.politicheantidroga.gov.it
Istituto Nazionale di Statistica (ISTAT). Official data on mortality causes in Italy including drug-related deaths. 2021.
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Report on drug-related deaths in Europe. 2019.
World Health Organization. Community management of opioid overdose [Internet]. Geneva: World Health Organization; 2014. Available from: https://www.who.int/publications/i/item/9789241548816
Chou R, Korthuis PT, McCarty D, et al. Management of Suspected Opioid Overdose With Naloxone by Emergency Medical Services Personnel [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2017 (Comparative Effectiveness Reviews, No. 193). Available from: https://www.ncbi.nlm.nih.gov/books/NBK487477/
Dezfulian C, Orkin AM, Maron BA, et al. American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Council on Clinical Cardiology. Opioid-Associated Out-of-Hospital Cardiac Arrest: Distinctive Clinical Features and Implications for Health Care and Public Responses: A Scientific Statement From the American Heart Association. Circulation 2021;143:e836-70.
World Health Organization (WHO). Report on the global opioid overdose crisis. 2021.
Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 2018;169:467-73.
Green BN, Johnson CD, Adams A. Writing narrative literature reviews for peer-reviewed journals: secrets of the trade. J Chiropr Med 2006;5:101-17.
Dixon-Woods M, Cavers D, Agarwal S, et al. Conducting a critical interpretive synthesis of the literature on access to healthcare by vulnerable groups. BMC Med Res Methodol 2006;6:35.
Skulberg AK, Tylleskär I, Valberg M, et al. Comparison of intranasal and intramuscular naloxone in opioid overdoses managed by ambulance staff: a double-dummy randomised controlled trial. Addiction 2022;117:1658-67.
Dietze P, Jauncey M, Salmon A, et al. Effect of Intranasal vs Intramuscular Naloxone on Opioid Overdose: A Randomized Clinical Trial. JAMA Netw Open 2019;2:e1914977. Erratum in: JAMA Netw Open 2020;3:e206593.
Skulberg A, Åsberg A, Khiabani HZ, et al. Pharmacokinetics of a novel, approved, 1.4 mg intranasal naloxone formulation for reversal of opioid overdose: a randomized controlled trial. Addiction 2019;114:859-67.
Skulberg A, Tylleskär I, Nilsen T, et al. Pharmacokinetics and -dynamics of intramuscular and intranasal naloxone: an explorative study in healthy volunteers. Eur J Clin Pharmacol 2018;74:873-83.
McDonald R, Lorch U, Woodward J, et al. Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study. Addiction 2018;113:484-93.
Yousefifard M, Vazirizadeh-Mahabadi MH, Neishaboori AM, et al. Intranasal versus Intramuscular/Intravenous Naloxone for Pre-hospital Opioid Overdose: A Systematic Review and Meta-analysis. Adv J Emerg Med 2019;4:e27.
Banerjee S, Wright MD. Injectable Opioid Agonist Treatment for Patients with Opioid Dependence: A Review of Clinical and Cost-Effectiveness [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020.
Wermeling DP. Review of naloxone safety for opioid overdose: practical considerations for new technology and expanded public access. Ther Adv Drug Saf 2015;6:20-31.
Gowing L, Ali R, White JM. Opioid antagonists with minimal sedation for opioid withdrawal. Cochrane Database Syst Rev. 2017;5:CD002021.
Bennett AS, Freeman R, Des Jarlais DC, Aronson ID. Reasons people who use opioids do not accept or carry no-cost naloxone: qualitative interview study. JMIR Form Res 2020;4.
Lewis CR, Vo HT, Fishman M. Intranasal naloxone and related strategies for opioid overdose intervention by nonmedical personnel: a review. Subst Abuse Rehabil 2017;8:79-95.
Grassin-Delyle S, Buenestado A, Naline E, et al. Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids. Pharmacol Ther 2012;134:366-79.
Rock P, Slavova S, Westgate PM, et al. Examination of naloxone dosing patterns for opioid overdose by emergency medical services in Kentucky during increased fentanyl use from 2018 to 2021. Drug Alcohol Depend 2024;255:111062.
Saari TI, Strang J, Dale O. Clinical pharmacokinetics and pharmacodynamics of naloxone. Clin Pharmacokinet 2024;63:397-422.
Walsh SL, El-Bassel N, Jackson RD, et al. The HEALing communities study: protocol for a cluster randomized trial to reduce opioid overdose deaths. Drug Alcohol Depend 2020;217:108335.
Oesterle S, Kuklinski MR, Hawkins JD, et al. Long-term effects of the communities that care trial on substance use, antisocial behavior, and violence through age 21 years. Am J Public Health 2018;108:659-65.
Irvine MA, Oller D, Boggis J, et al. Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: a modelling study. Lancet Public Health 2022;7.
Rzasa Lynn R, Galinkin JL. Naloxone dosage for opioid reversal: current evidence and clinical implications. Ther Adv Drug Saf 2018;9:63-88.
Lemen PM, Garrett DP, Thompson E, et al. High-dose naloxone formulations are not as essential as we thought. Harm Reduct J 2024;21:93.
Moe J, Godwin J, Purssell R, et al. Naloxone dosing in the era of ultra-potent opioid overdoses: a systematic review. CJEM 2020;22:178-86.
Weaver L, Palombi L, Bastianelli KMS. Naloxone administration for opioid overdose reversal in the prehospital setting: implications for pharmacists. J Pharm Pract 2018;31:91-8.
D'Orsogna MR, Böttcher L, Chou T. Fentanyl-driven acceleration of racial, gender and geographical disparities in drug overdose deaths in the United States. PLOS Glob Public Health 2023;3:e0000769.
Prekupec MP, Mansky PA, Baumann MH. Misuse of novel synthetic opioids: a deadly new trend. J Addict Med 2017;11:256-65.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
